Attainment of at least a very good partial response after induction treatment is an important surrogate of longer survival for multiple myeloma

Bone Marrow Transplantation

Volumn 45, Issue 11, 2010, Pages 1625-1630

  Tan, D ^a   Lao, Z ^a   Loh, Y ^a   Ng, H J ^a   Chuah, C ^a   Wong, G C ^a   Koh, M ^a   Linn, Y C ^a   Lim, L C ^a   Tien, S L ^a   Lee, L H ^a   Goh, Y T ^a   Hwang, W ^a  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

bortezomib; myeloma; SCT

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; MELPHALAN; PREDNISOLONE; THALIDOMIDE; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE MARKER; DRUG RESPONSE; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; SURVIVAL TIME; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; HUMANS; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78149470801     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2010.25     Document Type: Article

References (37)

1. Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495-2502. (Pubitemid 38010075)
2. Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006; 354: 1021-1030. (Pubitemid 43357806)
3. Cavo M, Di Raimondo F, Zamagni E, Patriarca F, Tacchetti P, Casulli AF et al. Short-term thalidomide incorporated into double autologous stem-cell transplantation improves out-comes in comparison with double autotransplantation for multiple myeloma. J Clin Oncol 2009; 27: 5001-5007.
4. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875-1883. (Pubitemid 36532313)
5. Lahuerta JJ, Martinez-Lopez J, Serna JD, Blade J, Grande C, Alegre A et al. Remission status defined by immunofixation vs. electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients. Br J Haematol 2000; 109: 438-446. (Pubitemid 30350732)
6. Van de Velde H, Liu X, Chen G, Cakana A, Deraedt W, Bayssas M. Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica 2007; 92: 1399-1406. (Pubitemid 350144158)
7. Wang M, Delasalle K, Feng L, Thomas S, Giralt S, Qazilbash M et al. CR represents an early index ofpotential long survival in multiple myeloma. 2009; (e-pub ahead ofprint 27 July 2009) PMID: 19633690.
8. Harousseau J-L, Attal M, Moreau P, Garban F, Facon T, Avet-Loiseau H. The prognostic impact of complete remission (CR) plus very good partial remission (VGPR) in a double transplantation program for newly diagnosed multiple myelo-ma (MM): combined results of the IFM 99 trials. Blood 2006; 108 (Abstract 3077).
9. Haessler J, Shaughnessy JD, Zhan F, Crowley J, Epstein J, van Rhee F et al. Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling. Clin Cancer Res 2007; 13: 7037-7079. (Pubitemid 350276890)
10. Barlogie B, Anaissie E, Haessler J, van Rhee F, Pineda-Roman M, Hollmig K et al. Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma. Cancer 2008; 113: 355-359.
11. Richardson PG, Mitsiadis C, Schlossman R, Munshi N, Anderson K. New drugs for myeloma. Oncologist 2007; 12: 664-689. (Pubitemid 47036203)
12. Jagannath S. Current standards for first-line therapy of multiple myeloma. Clin Lymphoma Myeloma 2007; 5: 207-214.
13. Kyle RA, Rajkumar SV. Multiple myeloma. Blood 2008; 111: 2962-2972.
14. Harousseau JL, Mathiot C, Attal M, Marit G, Caillot D, Hullin C et al. Bortezomib/dexamethasone versus VAD as induction prior to autologous stem cell transplantation (ASCT) in previously untreated multiple myeloma (MM): updated data from IFM 2005/01 trial. J Clin Oncol 2008; 26 (Abstract 8505).
15. Zonder JA, Crowley JJ, Bolejack V, Hussein M, Morre DF, Whittenberger BF et al. A randomized Southwest Oncology Group study comparing dexamethasone (D) to lenalidomide + dexamethasone (LD) as treatment of newly-diagnosed multiple myeloma (NDMM): impact of cytogenetic abnorma-lities on efficacy of LD, and updated overall study results. J Clin Oncol 2008; 26 (Abstract 8521).
16. Harousseau JL, Avet-Loiseau H, Attal M, Charbonnel C, Garban F, Hulin C et al. Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 trials. J Clin Oncol 2009; 27: 5720-5726.
17. Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006; 24: 431-436. (Pubitemid 46630462)
18. Palumbo A, Bringhen S, Caravita T, Merla E, Capparella V, Callea V et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006; 367: 825-831. (Pubitemid 43363369)
19. Mateos MV, Hernandez JM, Hernandez MT, Gutierrez NC, Palomera L, Fuertes M et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood 2006; 108: 2165-2172. (Pubitemid 44497496)
20. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M et al. Bortezomib plus melphalan and prednisone for initial treatment ofmultiple myeloma. N Engl J Med 2008; 359: 906-917.
21. Moreau P, Facon T, Attal M, Hulin C, Michallet M, Maloisel F et al. Comparison of 200mg/m(2) melphalan and 8 Gy total body irradiation plus 140mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 rando-mized trial. Blood 2002; 99: 731-735. (Pubitemid 34525530)
22. Durie BG, Harousseau JL, San Miguel JS, Blade J, Barlogie B, Anderson K et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467-1473. (Pubitemid 44264086)
23. Kaplan EL, Meier P. Nonparametric estimation from incom-plete observations. Am Stat assoc 1958; 53: 457-484.
24. Peto R, Pike MC. Conservatism of the approximation sigma (O-E)2-E in the log rank test for survival data or tumor incidence data. Biometrics 1973; 29: 579-584.
25. Anderson J, Cain K, Gelber R. Analysis of survival by tumor response. J Clin Oncol 1983; 1: 710-719. (Pubitemid 14202071)
26. Cox DR. Regression models and life-tables. J Royal Stat Soc B 1972; 34: 187-220.
27. Lahuerta J, Mateos M, Martinez-Lo'pez J, Rosinol L, Sureda A, de la Rubia J et al. Influence of pre-and post-transplantation responses on outcome ofpatients withmultiple myeloma: sequential improvement of response and achieve-ment of complete response are associated with longer survival. J Clin Oncol 2008; 26: 5775-5782.
28. Hoering A, Crowley J, Shaughnessy Jr JD, Hollmig K, Alsayed Y, Szymonifka J et al. Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in total therapy protocols. Blood 2009; 114: 1299-1305.
29. Dingli D, Pacheco JM, Nowakowski GS, Kumar SK, Dispenzieri A, Hayman SR et al. Relationship between depth of response and outcome in multiple myeloma. J Clin Oncol 2007; 25: 4933-4937. (Pubitemid 350220425)
30. Kumar S, Dingli D, Dispenzieri A, Lacy M, Hayman SR, Buadi F et al. Impact of additional cytoreduction following autologous SCT in multiple myeloma. 2008; 42: 259-264.
31. Ladetto M, Pagliano G, Avonto I, Santo L, Ferrero S, Cavallo F et al. Consolidation with bortezomib, thalidomide and dexamethasone induces molecular remissions in autografted multiple myeloma patients. Blood 2007; 110 (Abstract 163).
32. Arzoumanian V, Hoering A, Sawyer J, van Rhee F, Bailey C, Gurley J et al. Suppression of abnormal karyotypes is critical for prolonged survival in myeloma. Leukemia 2008; 22: 850-855. (Pubitemid 351552635)
33. Harousseau JL, Mathiot C, Attal M, Marit G, Caillot D, Mohty MM et al. Velcade/dexamethasone versus VAD as induction treatment prior to autologous stem cell transplantation in newly diagnosed patients: updated results of the IFM 2005/01 trial [abstract]. Blood 2007; 110 (Abstract 139).
34. Pineda-Roman M, Bolejack V, Arzoumian V, Anaissie E, van Rhee F, Zangari M et al. Complete response in myeloma extends survival, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease. Br J Haematol 2007; 136: 393-399. (Pubitemid 46046297)
35. van Rhee F, Bolejack V, Hollmig K, Pineda-Roman M, Anaissie E, Epstein J et al. High serum-free light chain levels and their rapid reduction in response define an aggressive multiple myeloma subtype with poor prognosis. Blood 2007; 110: 827-832. (Pubitemid 47267417)
36. Rajkumar SV, Jacobus S, Callander N, Fonseca R, Vesole D, Williams MV et al. Randomized trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed myeloma (E4A03), a trial coordinated by the Eastern Cooperative Oncology Group: analysis of response, survival, and outcome with primary therapy and stem cell transplantation. J Clin Oncol 2008; 26 (Abstract 8504).
37. Alexanian R, Weber D, Giralt S, Dimopoulos M, Delasalle K, Smith T et al. Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant 2001; 27: 1037-1043. (Pubitemid 32591186)